
================================================================================
JAVELIN.AI - DATA QUALITY EXECUTIVE SUMMARY
Generated: 2026-01-28 04:01:13
================================================================================

OVERVIEW
--------
Total Subjects: 57,997
Total Sites: 3,424
Studies: 23

RISK DISTRIBUTION
-----------------
Subject Level:
  * High Risk: 5,370 subjects (9.3%)
  * Medium Risk: 7,488 subjects (12.9%)
  * Low Risk: 45,139 subjects

Site Level:
  * High Risk Sites: 403 (11.8%)

REGIONAL ANALYSIS
-----------------
     ASIA: 13 countries, 689 sites, 8,504 subjects
     DQI: 0.067 | High-risk rate: 9.5% | vs Portfolio: +33.7%
     EMEA: 49 countries, 1478 sites, 27,514 subjects
     DQI: 0.050 | High-risk rate: 8.7% | vs Portfolio: -0.1%
     AMERICA: 7 countries, 1232 sites, 21,937 subjects
     DQI: 0.042 | High-risk rate: 9.8% | vs Portfolio: -17.2%
     Unknown: 3 countries, 25 sites, 42 subjects
     DQI: 0.012 | High-risk rate: 2.4% | vs Portfolio: -76.6%

COUNTRIES REQUIRING ATTENTION
-----------------------------
  [CRITICAL] DEU (EMEA): 90 sites, DQI=0.113, High-risk=13.3%
        → URGENT: 41 pending SAE reviews in DEU
  [CRITICAL] ISR (EMEA): 50 sites, DQI=0.097, High-risk=14.1%
        → URGENT: 66 pending SAE reviews in ISR
  [CRITICAL] TUR (EMEA): 59 sites, DQI=0.096, High-risk=9.5%
        → URGENT: 62 pending SAE reviews in TUR
  [CRITICAL] KOR (ASIA): 57 sites, DQI=0.095, High-risk=12.6%
        → URGENT: 84 pending SAE reviews in KOR
  [CRITICAL] AUS (ASIA): 64 sites, DQI=0.095, High-risk=13.5%
        → URGENT: 95 pending SAE reviews in AUS
  [CRITICAL] TWN (ASIA): 45 sites, DQI=0.079, High-risk=9.4%
        → URGENT: 42 pending SAE reviews in TWN
  [CRITICAL] SGP (ASIA): 25 sites, DQI=0.079, High-risk=15.9%
        → URGENT: 34 pending SAE reviews in SGP
  [CRITICAL] GRC (EMEA): 27 sites, DQI=0.078, High-risk=6.4%
        → URGENT: 7 pending SAE reviews in GRC
  [CRITICAL] BEL (EMEA): 35 sites, DQI=0.076, High-risk=19.7%
        → URGENT: 82 pending SAE reviews in BEL
  [CRITICAL] JPN (ASIA): 105 sites, DQI=0.071, High-risk=5.1%
        → URGENT: 9 pending SAE reviews in JPN

AI-GENERATED INSIGHT
--------------------
Executive Summary:

The clinical trial portfolio under review comprises 57,997 subjects across 3424 sites, spanning 23 studies. Notably, 9.3% of the total subject population is classified as high risk, with 51 critical sites identified. The portfolio is confronted by several significant issues: Max Days Outstanding (27,640), Lab Issues Count (6,846), and Pending SAE Reviews (6,496).

To address these challenges, immediate priority should be given to resolving the Max Days Outstanding issue by ensuring timely data entry and follow-up at site level. Simultaneously, increased focus is required on lab management, with prompt resolution of identified issues to maintain data integrity. Lastly, an accelerated review process for Pending SAEs is recommended to mitigate potential risks associated with adverse events.

CRITICAL ITEMS REQUIRING IMMEDIATE ACTION
-----------------------------------------
[!] PENDING SAE REVIEWS: 6496 subjects have SAE records awaiting review
    Action: Immediate pharmacovigilance review required

[!] CRITICAL SUBJECTS: 4531 subjects require immediate intervention
[!] CRITICAL SITES: 51 sites flagged for urgent quality review

TOP PRIORITIES THIS WEEK
------------------------
1. [CRITICAL] Study_1 - Site 17 (ESP)
   DQI Score: 0.516 | High-risk subjects: 2
   AI Insight: Given the critical risk level and DQI score of 0.516 for Site 17 in Study_1 within ESP, it is imperative to address the identified issues promptly to ensure data quality. The top priorities should foc...

2. [CRITICAL] Study_16 - Site 674 (DEU)
   DQI Score: 0.497 | High-risk subjects: 2
   AI Insight: Given the critical DQI score of 0.497 for Site 674 in DEU during Study_16, it is essential to address the identified issues promptly to maintain data quality. The top risks include a high number of SA...

3. [CRITICAL] Study_16 - Site 759 (TUR)
   DQI Score: 0.444 | High-risk subjects: 1
   AI Insight: Given the CRITICAL risk level and DQI score of 0.444 for Site 759 in TUR for Study_16, it is recommended to prioritize resolving the identified issues promptly. The primary focus should be on addressi...

4. [CRITICAL] Study_1 - Site 4 (FRA)
   DQI Score: 0.346 | High-risk subjects: 2
   Action: Schedule urgent site quality call within 48 hours

5. [CRITICAL] Study_1 - Site 27 (CHN)
   DQI Score: 0.343 | High-risk subjects: 2
   Action: Schedule urgent site quality call within 48 hours


RECOMMENDATIONS BY CATEGORY
---------------------------
* Max Days Outstanding: 27640 instances
  Priority: MEDIUM | Action: Escalate data entry delays to site

* Lab Issues Count: 6846 instances
  Priority: MEDIUM | Action: Reconcile lab data with central lab vendor

* Sae Pending Count: 6496 instances
  Priority: CRITICAL | Action: Immediate SAE review and regulatory submission required

* Inactivated Forms Count: 4049 instances
  Priority: LOW | Action: Review inactivated forms for audit trail compliance

* Missing Pages Count: 3620 instances
  Priority: MEDIUM | Action: Issue data query for missing CRF pages

* Missing Visit Count: 944 instances
  Priority: HIGH | Action: Contact site to schedule missed visits or document reason

* Edrr Open Issues: 599 instances
  Priority: LOW | Action: Resolve external data reconciliation discrepancies

* Uncoded Whodd Count: 434 instances
  Priority: LOW | Action: Code medication terms to WHODrug dictionary

* Uncoded Meddra Count: 327 instances
  Priority: HIGH | Action: Code adverse event terms to MedDRA dictionary


================================================================================
